NCT04179669View on ClinicalTrials.gov

Safety and Efficacy of IBI306 in HeFH Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

149

Participants

Timeline

Start Date

December 20, 2019

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Heterozygous Familial Hypercholesterolemia
Interventions
DRUG

IBI306

Administered by subcutaneous injection

DRUG

placebo

Administered by subcutaneous injection

Trial Locations (1)

Unknown

Beijing Anzhen Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04179669 - Safety and Efficacy of IBI306 in HeFH Patients | Biotech Hunter | Biotech Hunter